Department of Cardiology and Clinical Examination, Faculty of Medicine, Oita University, Yufu, Japan.
Department of Cardiovascular Medicine, Saga University, Saga, Japan.
J Cardiovasc Electrophysiol. 2020 Mar;31(3):682-688. doi: 10.1111/jce.14369. Epub 2020 Jan 31.
Atrial fibrillation (AF) is associated with heart failure (HF) rehospitalization in patients with heart failure with preserved ejection fraction (HFpEF).
We tested the hypothesis that catheter ablation of AF could reduce HF rehospitalization compared with conventional pharmacotherapy in patients with HFpEF.
Eighty-five consecutive HFpEF (EF ≥ 50% and a history of HF hospitalization) patients diagnosed as AF by 12-lead electrocardiogram were retrospectively analyzed. Thirty-five patients who received catheter ablation (ABL group) were compared with 50 patients treated by antiarrhythmic drugs and/or beta-blockers (CNT group). The primary endpoint was rehospitalization due to HF.
The patients characteristics did not differ between the two groups including, age (71 ± 8 vs 71 ± 13 years; P = .637), female sex (34% vs 36%; P = .870), mean plasma brain natriuretic peptide (145 ± 112 vs 195 ± 153 pg/mL; P = .111), mean left ventricular ejection fraction (62% ± 8% vs 61% ± 9%; P = .624), and type of AF (nonparoxysmal AF 60% vs 62%; P = .852). Amiodarone was continued 40% (14 out of 35) and 40% (20 out of 70) in ABL and CNT groups, respectively (P = 1.000). Neither major complication nor major side effect was observed during the follow-up period. During a mean follow-up period of 792 ± 485 days, Kaplan-Meier curve analysis showed that significantly more patients in the ABL group were free from HF rehospitalization (log-rank P = .0039). Additionally, multivariate analysis revealed that catheter ablation of AF was the only preventive factor of HF rehospitalization (OR = 0.15; 95% CI: 0.04-0.46; P < .001).
Catheter ablation of AF reduced HF rehospitalization compared with conventional pharmacotherapy in patients with HFpEF in our institute. Multicenter randomized study is warranted to confirm the result.
心房颤动(AF)与射血分数保留的心力衰竭(HFpEF)患者的心力衰竭再住院相关。
我们检验了这样一个假设,即在 HFpEF 患者中,与常规药物治疗相比,导管消融 AF 可降低心力衰竭再住院率。
回顾性分析了 85 例连续的 HFpEF(EF≥50%,并伴有心力衰竭住院史)患者的心电图,诊断为 12 导联心电图 AF。35 例接受导管消融(ABL 组)的患者与 50 例接受抗心律失常药物和/或β受体阻滞剂治疗的患者(CNT 组)进行比较。主要终点是心力衰竭再住院。
两组患者的特征无差异,包括年龄(71±8 岁 vs 71±13 岁;P=0.637)、女性(34% vs 36%;P=0.870)、平均血浆脑钠肽(145±112 比 195±153pg/mL;P=0.111)、平均左心室射血分数(62%±8% vs 61%±9%;P=0.624)和 AF 类型(非阵发性 AF 60% vs 62%;P=0.852)。ABL 和 CNT 组分别有 40%(14 例/35 例)和 40%(20 例/70 例)继续使用胺碘酮(P=1.000)。在随访期间,未观察到严重并发症或严重副作用。在平均 792±485 天的随访期间,Kaplan-Meier 曲线分析显示,ABL 组有更多的患者无心力衰竭再住院(对数秩 P=0.0039)。此外,多变量分析显示,AF 导管消融是心力衰竭再住院的唯一预防因素(OR=0.15;95%CI:0.04-0.46;P<0.001)。
与 HFpEF 患者的常规药物治疗相比,我院的 AF 导管消融可降低心力衰竭再住院率。需要进行多中心随机研究来证实这一结果。